BRANFORD, CT (May 4, 2017) –Thetis Pharmaceuticals, a pioneer in the development of novel lipid-based drugs for orphan gastrointestinal diseases, today announced that data from the company’s lead program will be presented at Digestive Disease Week (DDW), taking place in Chicago, May 6-9, 2017.
Details about this presentation are listed below:
TP-252, a Novel Derivative of Eicosapentaenoic Acid, Reduces Intestinal Tumor Burden in the ApcΔ14/+ Mouse Model of Familial Adenomatous Polyposis
- Date and time: Monday, May 8, 2017, 3:00 pm CT
- Presentation number: 652
- Presenter: Dr. Daniel Rosenberg, HealthNet Inc., Chair in Cancer Biology, Center for Molecular Medicine, University of Connecticut Health Center
- Location: Room S102D, McCormick Place, Chicago, IL
- Exhibit booth: #2004, New Exhibitor Pavilion
The abstract has been published in the Gastroenterology journal (link here).
About Thetis Pharmaceuticals
Thetis Pharmaceuticals is a biopharmaceutical company pioneering the development of novel lipid-based drugs for orphan gastrointestinal (GI) diseases. Using proprietary HEALER™ chemistry platform, Thetis creates unique derivatives of bioactive lipids that have improved pharmaceutical properties and strong intellectual property protection. This technology unlocks the robust biology of lipids that are clinically or preclinically known to have efficacy in treating GI diseases. The company’s lead candidate TP-252 is being developed for the treatment of familial adenomatous polyposis (FAP), a rare genetic disease which has no approved drug therapies. TP-252 is a new molecular entity that delivers eicosapentaenoic acid free fatty acid (EPA-FFA), a bioactive lipid with demonstrated clinical efficacy in controlling colorectal polyp burden in FAP patients. Thetis is also developing TP-252 for the treatment of ulcerative colitis based on phase 2 clinical data showing that EPA-FFA prevents relapse in patients at higher risk of flares. By leveraging the established clinical efficacy and safety of EPA-FFA, Thetis anticipates moving its TP-252 programs rapidly into clinical development, facilitated by minimal non-clinical toxicology requirements and 505(b)(2) NDA submissions.
# # #
Jenna R. Conley
Director, Business Development